Drug Profile

Efzimfotase alfa - Alexion AstraZeneca Rare Disease

Alternative Names: ALXN-1850

Latest Information Update: 21 Aug 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Alexion Pharmaceuticals
Developer Alexion AstraZeneca Rare Disease
Class Recombinant fusion proteins
Mechanism of Action Alkaline phosphatase replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preregistration Hypophosphatasia

Most Recent Events

27 Jul 2026 Preregistration for Hypophosphatasia in Japan (SC) (AstraZeneca pipeline, July 2026)
28 Jun 2026 Adverse events and efficacy data from the CHESTNUT Phase III trial in Hypophosphatasia released by AstraZeneca
28 Jun 2026 Updated efficacy data from the phase III MULBERRY trial in Hypophosphatasia released by AstraZeneca

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com